Showing 761-770 of 1867 results for "".
- Obagi Launches SKINCLUSION Initiative to Celebrate Diversity with Brand Ambassador Priyanka Chopra Jonashttps://practicaldermatology.com/news/obagi-launches-skinclusion-initiative-to-celebrate-diversity-with-brand-ambassador-and-priyanka-chopra-jonas/2460026/Obagi kicked off its SKINCLUSION initiative, designed to elevate the global dialogue about diversity and how we can all make conscious choices to see the beauty in all of our differences, with an event in New York City introducing Priyanka Chopra Jonas as its SKINCLUSION ambassador. Priyanka, an
- Meet JOULE X and More New Offerings from Sciton at ASLMShttps://practicaldermatology.com/news/meet-joule-x-and-more-new-offerings-from-sciton-at-aslms/2459954/Sciton Inc. unveiled JOULE X and other new offerings at the annual American Society for Laser Medicine and Surgery Meeting in Denver, Colorado. An upgrade to the JOULE platform, JOULE X is the company’s latest multi-device platform. It work
- Jean Bolognia, MD Honored with AAD Gold Medalhttps://practicaldermatology.com/news/jean-bolognia-md-honored-with-aad-gold-medal/2459966/During the 2019 Annual Meeting of the American Academy of Dermatology (AAD) in Washington, D.C., the AAD awarded Jean Bolognia, MD, Professor of Dermatology at the Yale University School of Medicine, with its Gol
- FDA Approves Janssen's Tremfya One-Presshttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-one-press/2459882/The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson
- Jeuveau from Evolus Now FDA Cleared for Aesthetic Injectionhttps://practicaldermatology.com/news/jeuveau-from-evolus-now-fda-cleared-for-aesthetic-injection/2459914/The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this sp
- Alan Menter, MD Receives Outstanding Researcher and Educator in Psoriatic Disease Award from ODAC, JDDhttps://practicaldermatology.com/news/alan-menter-md-receives-outstanding-researcher-and-educator-in-psoriatic-disease-award-from-odacjdd/2459929/Alan Menter, MD, has been awarded the Outstanding Researcher and Educator in Psoriatic Disease Award by the ODAC Dermatology, Aesthetics & Surgical Conference, in partnership with the Journal of Drugs in Dermatology (JDD). The award recognizes Dr. Menter’
- JAK Kinase Inhibitors Show Promise in Treating Alopeciahttps://practicaldermatology.com/news/jak-kinase-inhibitors-show-promise-in-treating-alopecia/2459947/UPDATED -- New research suggests selective oral JAK kinase inhibitors may play a role in treating moderate-to-severe alopecia areata (AA). The findings were presented at the Inflammatory Skin Disease Summit in Vienna, Austria. In this
- Dr. Sandra Marchese Johnson, Yoseph Dalia Win Practical Dermatology®'s Best Paper of 2018 Awardhttps://practicaldermatology.com/news/dr-sandra-marchese-johnson-yoseph-dalia-win-practical-dermatologys-best-paper-of-2018-award/2459950/Fort Smith, Arkansas-based dermatologist Sandra Marchese Johnson MD, FAAD and Yoseph Dalia, BS took home Practical Dermatology®’s Best Paper of 2018 award for a Resident Resource Center submission that detailed the first reported case of facial rash following dupilumab
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track
- New Xeomin "Later Haters" Campaign Urges Women to “X” Out Judgmenthttps://practicaldermatology.com/news/new-xeomin-later-haters-campaign-aims-to-x-out-judgment/2457487/Merz Americas is launching a new advertising campaign for Xeomin (incobotulinumtoxinA) called “Later Haters,” which urges women to “X out” judgment, stop apologizing for caring about how they look and put an end to f